Newsroom

Sorted by: Latest

-

Resumen: Avanzanite anuncia una colaboración paneuropea con Agios para lanzar PYRUKYND® contra las enfermedades raras de la sangre

ÁMSTERDAM--(BUSINESS WIRE)--Avanzanite Bioscience B.V. («Avanzanite»), una compañía farmacéutica especializada en fase comercial de rápido crecimiento centrada en ofrecer medicamentos para enfermedades raras a pacientes de toda Europa, ha anunciado hoy un acuerdo exclusivo con Agios Pharmaceuticals Inc. (Nasdaq: AGIO), una compañía biotecnológica con sede en Boston centrada en el desarrollo y la comercialización de medicamentos para enfermedades raras. El comunicado en el idioma original es la...
-

Alliance for Food and Farming: “Dirty Dozen” List Recommendations Cannot Be Substantiated

WATSONVILLE, Calif.--(BUSINESS WIRE)--Peer reviewed research published in the Journal of Toxicology found that the recommendation in the “Dirty Dozen” list to substitute organic forms of produce for conventional does not result in any decrease in risk for consumers because residues on conventionally grown are so low, if present at all. The research also found that the list authors follow no scientifically established methodology in the development of their list. In fact, the “Dirty Dozen” list...
-

macOS Tahoe 26 makes the Mac more capable, productive, and intelligent than ever

CUPERTINO, Calif.--(BUSINESS WIRE)--Apple® today previewed the next major macOS® release — macOS Tahoe 26 — which introduces a stunning new design and powerful capabilities that enable users to get even more done. With the new design, iconic elements of macOS will feel more expressive, delightful, and personal while remaining instantly familiar, including the desktop, Dock, in-app navigation, and toolbars. Users can further personalize the experience with an updated Control Center and new color...
-

Moat Metrics Announces Innovation Alpha New Feature Release - The Invention Disclosure Analyzer

SPOKANE, Wash.--(BUSINESS WIRE)--Filing a patent is expensive—and deciding what to patent versus what to keep as a trade secret has always been a high-stakes decision. But what if you could make those calls faster, with better data, and less effort? Today, Moat Metrics is excited to announce the launch of The Invention Disclosure Analyzer, a powerful new feature in Innovation Alpha designed to help R&D, legal, and tech transfer teams streamline the invention review process and unlock the st...
-

Wolters Kluwer announces Joel Morris as new Vice President & Segment Leader, Research & Advisory in Tax & Accounting

MINNEAPOLIS--(BUSINESS WIRE)--Wolters Kluwer Tax and Accounting (TAA) is pleased to announce the appointment of Joel Morris as the new Vice President & Segment Leader, Research & Advisory. In this role, Joel will be responsible for meeting the financial performance, customer satisfaction, and market growth targets for the Segment. He will lead the strategic transformation of the division’s digital content business in the U.S. and Canada further accelerating the Tax & Accounting divi...
-

Maximus Unveils Total Experience Management (TXM) Solution with New AWS Integrations to Help Agencies Deliver Services More Efficiently and Effectively

TYSONS, Va.--(BUSINESS WIRE)--Maximus (NYSE: MMS), a leading employer and provider of government services, today announced the latest version of its industry-leading customer experience (CX) solution, Total Experience Management (TXM), powered by Amazon Web Services (AWS). Maximus TXM was launched in 2024 and enables agencies to implement the next generation of CX through one comprehensive solution with FedRAMP-authorized technologies. Through its strategic collaboration with AWS, Maximus lever...
-

Lubrizol Announces an Important Milestone for Its Novel Patented Excipient, Apisolex™ Polymer

CLEVELAND--(BUSINESS WIRE)--Lubrizol announces that an Apisolex™ polymer excipient-enabled drug formulation is in Phase 1 clinical trials. Introduced to the market in 2022, Apisolex polymer excipient is a polyamino acid-based polymer that enhances the solubility of BCS Class II and IV active pharmaceutical ingredients (API). Apisolex polymer excipient is manufactured following Good Manufacturing Practices (GMP) guidelines and can be used in dosage forms for various routes of administration, inc...
-

Crain’s New York Business Names Bart M. Schwartz as Notable Leader in Philanthropy

NEW YORK--(BUSINESS WIRE)--Guidepost Solutions, a global leader in domestic and international investigations, compliance solutions, monitoring, and security and technology consulting, is proud to announce that its Co-Founder and Chairman, Bart M. Schwartz, has been selected as one of Crain’s 2025 New York Business Notable Leaders in Philanthropy. Honorees are selected through a peer nomination and editorial review process and the annual award recognizes leaders for their professional achievemen...
-

New Research Underscores the Important Role of Value-Based Care (VBC) in Improving Primary Care Access for Traditional Medicare Patients

WESTERVILLE, Ohio--(BUSINESS WIRE)--agilon health (NYSE: AGL), the trusted partner empowering physicians to transform health care in our communities, today announced new research demonstrating the promising role of value-based care (VBC) in maintaining primary care for senior patients when supported by agilon health, a VBC-enablement company. The study was published in the May 2025 issue of Health Affairs Scholar. “Primary care is foundational for Medicare beneficiaries, especially those with c...
-

US Acute Care Solutions Reduces Opioid Prescriptions Through Emergency Department Feedback Program

CANTON, Ohio--(BUSINESS WIRE)--US Acute Care Solutions (USACS) is pleased to share its success in reducing opioid prescribing rates in emergency departments (EDs) nationwide. This achievement is the result of an audit and feedback quality improvement program, designed to limit excessive prescribing in several practice settings and health systems. The Growing Epidemic Since 1999, over one million Americans have lost their lives to a drug overdose, making it the leading cause of death among those...